Amanta Healthcare Ltd(AMANTA)

NSE: AMANTABSE: 544502

₹ 168.4+3.19%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 654 crWebsite: www.amanta.co.inUpdated: 27 Oct 2026

About

Amanta Healthcare is an Ahmedabad-based pharmaceutical company specialising in sterile liquid parenterals, making Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) using ABFS and ISBM technologies. It was the first company to bring ISBM technology to India and holds a 50 - 60% domestic market share in this segment. Revenue was Rs 287.68 crore in FY26.^[1][2]

Business segments

SteriPort (ISBM two-port IV fluid platform) contributed about 44% of revenue in Q1 FY27, vs nearly 42% of revenue from operations in FY26.^[3][4]
Small Volume Parenterals (SVP) contributed about 20% of revenue in FY26; 90% of SVP revenue comes from exports, and more than 60% of that from advanced or semi-advanced markets.^[3]
Inhalation solutions and preservative-free ophthalmics contributed nearly 20% of SVP revenue in FY26.^[4]
Alongside its own brands, Amanta runs a product partnering and contract manufacturing business for domestic and international pharma companies.^[1]

Products and portfolio

The portfolio spans six therapeutic segments: fluid therapy (IV fluid), formulations, diluents and injectables, ophthalmic, respiratory care and irrigation solutions (FY26).^[1]
47 products are registered across 120 international jurisdictions (FY26).^[1]
About 20 products are under development (FY26). Management expects the 20-product SVP pipeline (inhalation, ophthalmics, diluents) to be fully developed within 18 months of the Q1 FY27 call.^[1][3]
Two-port IV systems are growing at 12-13% versus 8-10% for the LVP industry, according to management on the Q4 FY26 call.^[4]

Manufacturing and operations

All manufacturing takes place at a single facility near Kheda, Ahmedabad, spread over 25 acres with a built-up area of 25,000 sq. mts (FY26).^[1]
The facility fills volumes from 2 ml to 1,000 ml across multiple closure systems.^[1]
Certifications: ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018 and WHO-GMP.^[1]
SteriPort capacity stood at 6.6 crore bottles per year before Line 3, which is taking it to roughly 12 crore bottles per year.^[4]
A 10.8 MW captive solar power plant costing INR 34.8 cr was commissioned in June 2026. Management expects it to save about INR 9 cr a year (INR 75 lakh a month).^[3]

Capacity utilisation

SteriPort utilisation rose to 90% in FY26 from 73% in FY23.^[1]
SVP utilisation rose to 98% in FY26 from 89% in FY23.^[1]
LVP utilisation was 93% in FY26, compared with 97% in FY23.^[1]
Overall utilisation reached 96% in FY26.^[1]

Customers and markets

Exports were 39% of revenue in FY26, up from 32% in FY25.^[4][5]
Top export markets include Thailand, the UK, the Philippines and Sudan/South Sudan. The company markets its products in 25-30 countries (FY26).^[4]
Amanta has had a presence in the United Kingdom for more than two decades.^[1]
About 85% of revenue comes from frontline operations (FY26).^[1]
SteriPort use is spreading beyond specialty centres to small and mid-size nursing homes (Q4 FY26 call).^[4]

Expansion and capex

SteriPort Line 3 has a total capex of INR 90 cr, of which INR 80 cr had been spent as of Q1 FY27. Commercial production was targeted for the last week of August 2026, subject to an FDA inspection on 21 August.^[3]
SteriPort Line 3 is expected to generate about INR 120 cr of annualised revenue, with about INR 70 cr in the remaining 7 months of FY27.^[3]
A new SVP line is expected to start commercial production in February-March 2027, with factory acceptance testing in the USA in November 2026 and the machine on site in December 2026.^[3]
Management targets 60-70% of SVP revenue from advanced markets, including ophthalmics for the EU, Australia and Canada, once the new capacity is commissioned.^[3]
Management is exploring other dosage forms and packaging materials beyond plastic, such as glass, and expects clarity by December 2026-January 2027.^[3]

Recent developments

SteriPort Line 3 commissioning slipped from Q1 FY27 to Q2 FY27 because of delays in civil construction. FDA plan approval was received in August 2026.^[3]
The first SVP inhalation product (a respule) was targeted for commercialisation by 15 September 2026.^[3]
Polymer prices rose about 70-80% for about 2 months in Q1 FY27 because of the Middle East crisis. The company raised selling prices by INR 1.50 per unit against a cost increase of INR 2.25 per unit.^[3]
CRISIL upgraded the company's rating by one notch to BBB (Q4 FY26 call).^[4]
The company raised INR 20 Cr through a private placement of 2,000,000 shares at INR 100 each and fully repaid its outstanding NCDs.^[5]

Market Cap

₹654 Cr

High / Low

₹210 / 93

Stock P/E

42.9

Price / Book

2.9

Book Value

₹57

EPS

₹3.8

No. of Shares

3.88 Cr

ROCE

9.8%

ROE

6.8%

OPM

15.3%

Debt / Equity

1.06

Sales

₹288 Cr

Net Profit

₹15 Cr

Promoter holding

63.8%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials